RxDoctor Payments Data

Shawn Garcia, PA

Physician Assistant · Brooklyn, NYNPI 1306142906

Payments from drug & device makers

$9,106in general payments, 2019–2025

Across 661 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • Otsuka America Pharmaceutical, Inc.$865
  • Bayer$563
  • Amgen$514
  • Abbott$429
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,106100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,106 in reported general payments places this provider in the 95th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$49,126
Medicare patients
241
Services billed
1,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$92,461
OtezlaApremilast11$50,628
EliquisApixaban18$25,644
LinzessLinaclotide13$19,787
KerendiaFinerenone15$19,594
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,270
JanuviaSitagliptin Phosphate15$19,267
RybelsusSemaglutide11$18,086
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$2,988
Gabapentin114$1,907
Albuterol Sulfate HfaAlbuterol Sulfate77$1,851
Atorvastatin Calcium193$1,198
ValacyclovirValacyclovir Hcl13$948
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$915
Metoprolol Succinate41$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,031$110,54770 claims
AmgenOtezla$514$50,62811 claims
PfizerEliquis$154$25,64418 claims
AbbVieLinzess$1,793$19,78713 claims
BayerKerendia$563$19,59415 claims
GSKTrelegy Ellipta$222$19,27015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →